ALS in Biological Technology

Bay Area Youth to Represent ALS Patients at Giants' and Angels' Baseball Games on July 4th

SAN FRANCISCO, July 3 /PRNewswire-USNewswire/ -- Tomorrow, Corey Reich, an ALS patient from Piedmont, California, will attend both the San Francisco Giants and Los Angeles Angels of Anaheim baseball games this July 4th as a representative of the ALS Therapy Development Institute (ALS TDI). Corey ...

Seminar Will Bring ALS Researchers to Patient Groups

The Leading ALS Lab Presents on Therapy Development Strategy CAMBRIDGE, Mass., Feb. 17 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) has announced the 2009 launch of its popular ALS Research 101 series. The two-hour, interactive seminar is designed to inform and ...

Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit

ROCKVILLE, Md., Sept. 8 /PRNewswire-FirstCall/ -- Neuralstem Inc., CEO, Richard Garr, will be a featured panelist discussing stem cells and ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at the 2008 World Stem Cell Summit in Madison, Wisconsin, on September 22, at 2:00 CDT. In a ...

UW-Madison step in ALS research; student business plans; tech recycling

UW-Madison researchers may be moving toward a treatment for ALS, a nerve-system disease, using stem cells. Also, students excel at the G. Steven Burrill Technology Business Plan Contest, and Madison offers a computer and television recycling program. Original air date: Saturday, April 23, 2005 L...

UW-Madison rat experiment could lead to stem-cell treatment for ALS

Madison, Wis. Scientists at the University of Wisconsin-Madison have sucessfully injected stem cells into rats' spines in a way that could lead to treatments for degenerative diseases but they did not use the controversial embryonic stem cells. The researchers inserted human stem cells deriv...

Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients

...the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin) for Parkinson's disease. CERE-135 and CERE-140 are in preclinical development for als (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001. The company's investors include Alta Partners, MPM...

Bilayer graphene gets a bandgap

...Source." Using infrared beamline 1.4 at the ALS, under the direction of als physicist Michael Martin and Zhao Hao of the Earth Sciences Division, Wang ...malleable electronic structure of bilayer graphene The results from the als measurements were obtained with relative ease and efficiency, and showed th...

BASF Sues DuPont for Patent Infringement

...rporates BASF's patented promoter which is an important genetic component that enables successful tolerance toward an herbicide class known as AHAS or als inhibitors. BASF Plant Science GmbH seeks an injunction and damages against DuPont and its subsidiary Pioneer Hi-Bred International for this unla...

Campaign to Increase the Awareness and Understanding of Lou Gehrig's Disease Reaches 22 U.S. States

... Non-Profit Biotech Calls on the Entire als Community to Join a Nationwide Network of Independ...IDGE, Mass., May 18 /PRNewswire-USNewswire/ -- The als Therapy Development Institute (ALS TDI) announced its BBQ For als Awareness , is a national initiative designed to i...

Insmed Announces First Quarter 2009 Financial Results

... Generated $2.0 million in cost recovery revenue from the IPLEX(TM) EAP for als in Italy during the first quarter of 2009. ...se 2 results in MMD before the end of the second quarter. In addition, the als EAP is set to expand internationally via our agreement with IDIS, and we ar...

ALS Therapy Development Institute, the World's Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer

... and Maureen Lister was appointed president of the als Therapy Development Institute (ALS TDI) during the...imply put, the research and development program at als TDI is the most comprehensive one possible today. Under Steve's leadership, the als TDI research team has produced tangible results th...

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.

...m is now addressing. In a Phase I trial, the Company aims to study the safety and feasibility of injecting its cells directly into the spinal cords of als patients, where the healthy, fully functional cells are expected to replace or repair damaged and missing nerve cells. About Crystal Research A...

Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)

... INSMED WILL CONTINUE TO MANAGE als EAP IN ITALY AND ALL IPLEX(TM) INITIATIVES IN THE U.S. IDIS WILL HAVE RESPONSIBILITY FOR REST OF WORLD RICHMOND, Va., March 30 /PRNews...

Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results

...hts for IPLEX(TM) in connection with potential EAP als programs outside of Italy; The Europea...covery revenue from our EAP to treat patients with als in Italy. The net loss for the fourth quarter... cost recovery from the EAP to treat patients with als in Italy and the grant receipt of $1.0 million fro...

Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results

...o initiated a Phase 2 clinical trial (SB-509-801) to evaluate SB-509, a ZFP transcription factor (ZFP TF(TM)) VEGF-A activator, in subjects with ALS. als is a progressive, degenerative motor-neuron disease for which there are limited treatment options and no cure. The rationale for the study is based on...

Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference

...ompany filed an IND (Investigational New Drug) application with the FDA for als clinical trials in December, 2008, and has entered into a collaborative agr... pre-clinical work, the company's cells have extended the life of rats with als (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collabor...

Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent

...ompany filed an IND (Investigational New Drug) application with the FDA for als clinical trials in December, 2008, and has entered into a collaborative agr... pre-clinical work, the company's cells have extended the life of rats with als (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collabor...

Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease

...ter a Phase 2 study for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin). CERE-135 and CERE-140 are in preclinical development for als (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001. The company's investors include Alta Partners, MPM ...

Isis Reports Financial Results and Highlights for Third Quarter of 2008

...eated with ISIS 113715 and sulfonylureas -- Initiate a Phase 1 study on ISIS 333611, Isis' first CNS drug targeting SOD1 for the treatment of als -- Potential acquisition of Ibis by Abbott Financial Results For the first nine months of 2008, Isis had a pro forma net operating loss (NOL) of ...

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008

...llion increase in cost recovery revenue from our EAP to treat patients with als in Italy and the grant receipt of $1.0 million from the Muscular Dystrophy ....5 million improvement in cost recovery from our EAP to treat patients with als in Italy and the grant receipt of $1.0 million from the Muscular Dystrophy ...

Sangamo BioSciences Reports Third Quarter 2008 Financial Results

... evaluate SB-509 in subjects with Amyotrophic Lateral Sclerosis (ALS). als is a progressive, degenerative motor-neuron disease for which there are...9, the study will also evaluate stem cell mobilization in subjects with als receiving SB-509. * Presentation of additional data from Phase 1b stu...

Neuralstem Reports Second Quarter Financial Results and Highlights

...o manage the Company's upcoming clinical trial for als (Amytrophic Lateral Sclerosis, or Lou Gehrig's dis...ompany's cells have extended the life of rats with als (Lou Gehrig's disease) as reported the journal TRA...stigational New Drug) application with the FDA for als in the fall. Cautionary Statement Regarding Forw...

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008

...rresponding period in 2007. The increase was primarily attributable to a $1.4 million improvement in cost recovery from our EAP to treat patients with als in Italy. This was partially offset by the absence of license income from our agreement with Napo Pharmaceuticals Inc., ("Napo") from which we receive...

Isis Reports Financial Results and Highlights for Second Quarter of 2008

...GR for the treatment of type 2 diabetes -- Initiate Phase 1 study on ISIS 333611, Isis' first CNS drug targeting SOD1 for the treatment of als -- Advance a second new drug candidate into development -- Potential acquisition of Ibis by Abbott Financial Results Isis had $873,000 of pro ...

Neuralstem Fills Key Product Development Position

... FOCUS ON als CLINICALS AND DRUG DEVELOPMENT ROCKVILLE, Md., July 30 /PRNewswire-FirstC...eases and injuries of the spinal cord for its first human trials, including als and Paraplegia. The company has also developed neurogenic and neuroprotec...

ALS Therapy Development Institute and California Stem Cell, Inc. Announce Long-Term Scientific Collaboration

...ny potential application of stem cells in treating als - amyotrophic lateral sclerosis, commonly known as...nerative disease. "It is no mystery to us in the als community that stem cells ought to be looked at an...top ALS," said Sean Scott, president of ALS TDI. als is a neurodegenerative disease resulting in progre...

Rentschler Biotechnologie erweitert Kapazitten fr Produktion in Sugetierzellen

...Grund hat Rentschler Biotechnologie seit 2002 mehr als 70 Millionen Euro in die Erweiterung seiner Produk... investiert. Dadurch hat Rentschler seine Position als Auftragshersteller für Biopharmazeutika gefes...ntschler Gruppe mit Sitz in Laupheim, Deutschland. als internationales Full-Service-Auftragsunternehmen m...

Neuralstem Responds to New StemCells, Inc. Lawsuit

...rograms currently underway include: Ischemic Paraplegia, Traumatic Spinal Cord Injury and ALS. The company's cells have extended the life of rats with als (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysi...

Insmed Announces First Quarter 2008 Financial Results

...rresponding period in 2007. The increase was primarily attributable to a $1.6 million improvement in cost recovery from our EAP to treat patients with als in Italy. This was partially offset by the revenues lost from our withdrawal of IPLEX(TM) in the short stature market pursuant to the terms of our Mar...

Neuralstem Sues StemCells, Inc. Over New Patent

...rograms currently underway include: Ischemic Paraplegia, Traumatic Spinal Cord Injury and ALS. The company's cells have extended the life of rats with als (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysi...

Ceregene Announces Two Key Additions to Leadership Team

...rturin) which has completed enrollment of a controlled Phase 2 study for Parkinson's disease. CERE-135 and CERE-140 are in preclinical development for als (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001. The company's investors include Alta Partners, MPM C...

Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial

...diseases). Near term, the Company plans to initiate a Phase III trial in Huntington's disease as discussed above and a confirmatory Phase III trial in als to accompany the ongoing NIH Phase III trial in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerate...

Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation

...ograms currently underway include: Ischemic Paraplegia, Traumatic Spinal Cord Injury, and ALS. The company's cells have extended the life of rats with als (Lou Gehrig's disease) in a paper published in the journal TRANSPLANTATION in collaboration with John's Hopkins University researchers and also revers...

Avicena Group to Present at 10th Annual BIO CEO & Investor Conference

...aceutical program centers on rare neurological disorders (orphan diseases). Near term, the company plans to initiate a confirmatory Phase III trial in als and a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trial in Parkinson's disease. Avicena's science is well establish...

Avicena to Present at 4th Annual BIO InvestorForum Conference

...aceutical program centers on rare neurological disorders (orphan diseases). Near term, the company plans to initiate a confirmatory Phase III trial in als and a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trail in Parkinson's disease. Avicena's science is well establish...

KineMed to Present at the 4th Annual BIO Investor Forum

...bolic disorders including atherosclerosis, and diabetes and dyslipidemia. Mr. Fineman will also discuss KineMed's internal drug development program in als and provide an overview on the company's partnering and collaboration efforts, including KineMed's clinical development collaborations with Merck & Co...

Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer

...nd CERE-120 (AAV2-Neurturin) currently in a controlled Phase 2 study for Parkinson's disease. CERE-130 and CERE-140 are in preclinical development for als (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001, and the company's investors include Alta Partners, M...

Avicena Appoints Dr. M. Flint Beal to Board of Directors

...age with Phase III studies in Parkinson's Disease, Huntington's Disease and als and we are looking forward to Dr. Beal's contributions." Dr. Beal is the A...tudy Group, Parkinson's Disease Foundation, Bachman-Strauss Foundation, The als Association, and the American Health Assistance Foundation. Author or co-a...

Patent Office Rules in Neuralstem's Favor in Dispute with StemCells, Inc.

... include: Ischemic Paraplegia, Traumatic Spinal Cord Injury, ALS, and Parkinson's disease. The company's cells recently extended the life of rats with als (Lou Gehrig's disease) in a paper published in the journal TRANSPLANTATION, and were deemed viable for continued work in neurodegenerative spinal cond...

Avicena Reports Second Quarter 2007 Results

...ntly in Phase III testing with the National Institutes of Health in one of the largest Parkinson's disease trials ever conducted. AL-02, the company's als candidate, and HD-02, its treatment for Huntington's disease, are soon expected to enter Phase III testing. Unlike traditional biotechnology companies...